XML 30 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Treasury Stock
Balance at beginning of period ( in shares) at Dec. 31, 2021   388.0        
Balance at beginning of period at Dec. 31, 2021 $ 2,042.1 $ 0.4 $ 2,108.7 $ 0.5 $ 138.7 $ (206.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity incentive plans (in shares)   1.6        
Issuance of common stock for employee stock purchase plan (in shares)   0.3        
Issuance of common stock for Employee Stock Purchase Plan $ 22.5   22.5      
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 2.9 2.9        
Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs $ (0.1)   (189.3)     189.2
Purchases of treasury stock, including excise tax (in shares)   (6.6)        
Purchases of treasury stock, including excise tax (557.7)         (557.7)
Tax benefit related to Senior Convertible Notes $ (0.4)   (0.4)      
Conversions of 2023 Notes (in shares) 0.4 0.4        
Conversions of 2023 Notes $ 17.4   4.2     13.2
Benefit of note hedge upon conversions of 2023 Notes (in shares) (0.3) (0.3)        
Benefit of note hedge upon conversions of 2023 Notes $ 0.0   33.5     (33.5)
Exercise and settlement of warrants (in shares) 0.0          
Share-based compensation expense $ 126.5   126.5      
Capitalization of sales-based milestones 152.4   152.4      
Net income 341.2       341.2  
Other comprehensive income, net of tax (12.1)     (12.1)    
Balance at end of period (in shares) at Dec. 31, 2022   386.3        
Balance at end of period at Dec. 31, 2022 2,131.8 $ 0.4 2,258.1 (11.6) 479.9 (595.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity incentive plans (in shares)   1.4        
Issuance of common stock for employee stock purchase plan (in shares)   0.3        
Issuance of common stock for Employee Stock Purchase Plan $ 26.6   26.6      
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 3.7 3.7        
Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs $ (0.2)   (323.4)     323.2
Purchases of treasury stock, including excise tax (in shares)   (6.3)        
Purchases of treasury stock, including excise tax (689.2)   (0.2)     (689.0)
Tax benefit related to Senior Convertible Notes $ (4.4)   (4.4)      
Conversions of 2023 Notes (in shares) 0.0 12.2        
Conversions of 2023 Notes $ (13.1)   (13.1)      
Benefit of note hedge upon conversions of 2023 Notes (in shares) (12.2) (12.2)        
Benefit of note hedge upon conversions of 2023 Notes $ 6.2   1,496.5     (1,490.3)
Purchase of capped call transactions, net of tax $ (76.3)   (76.3)      
Exercise and settlement of warrants (in shares) 0.0          
Share-based compensation expense $ 150.8   150.8      
Net income 541.5       541.5  
Other comprehensive income, net of tax $ (5.1)     (5.1)    
Balance at end of period (in shares) at Dec. 31, 2023 385.4 385.4        
Balance at end of period at Dec. 31, 2023 $ 2,068.6 $ 0.4 3,514.6 (16.7) 1,021.4 (2,451.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity incentive plans (in shares)   1.3        
Issuance of common stock for employee stock purchase plan (in shares)   0.4        
Issuance of common stock for Employee Stock Purchase Plan $ 28.2   28.2      
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 1.5 1.5        
Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs $ 0.0   (188.1)     188.1
Purchases of treasury stock, including excise tax (in shares)   (10.4)        
Purchases of treasury stock, including excise tax $ (749.5)         (749.5)
Conversions of 2023 Notes (in shares) 0.0          
Benefit of note hedge upon conversions of 2023 Notes (in shares) 0.0          
Exercise and settlement of warrants (in shares) 12.5 12.5        
Exercise and settlement of warrants $ 0.0   (1,431.3)     1,431.3
Share-based compensation expense 170.4   170.4      
Net income 576.2       576.2  
Other comprehensive income, net of tax $ 8.7     8.7    
Balance at end of period (in shares) at Dec. 31, 2024 390.7 390.7        
Balance at end of period at Dec. 31, 2024 $ 2,102.6 $ 0.4 $ 2,093.8 $ (8.0) $ 1,597.6 $ (1,581.2)